Loblaw's GLP-1 Inflection and the Bank Heir's Exit: A Retailer Reshaping Its Profit Mix

Canada's largest grocer completes its PC Financial divestiture into EQ Bank while positioning for a generics-driven pharmacy windfall and doubling down on discount banners in a value-hungry consumer market.

L.TO · Earnings Call · 2026-07-30

The Quiet Strategic Pivot

Loblaw's second quarter was defined less by its headline 4.1% revenue growth than by what it chose to do with its cash. The company completed the long-awaited sale of PC Financial to EQ Bank, receiving $625 million in cash and a 19.9% ownership stake in EQB — a stake management plans to grow to approximately 25% by November 2027. This is a genuine strategic pivot: the grocer is stepping out of the banking business entirely, yet keeping a seat at the table for the loyalty ecosystem that matters most. The CFO framed it plainly, acknowledging the transition mechanics without overpromising: “Because the PC Financial transaction closed partway through the quarter and our reporting calendars are different, we will only recognize 1 month of EQB's earnings in the third quarter. Despite this timing related headwind, we remain confident in our ability to deliver net earnings per common share growth in the high single digits.” — Richard Dufresne, Chief Financial Officer · 2026-07-30 The pivot frees up capital: share buybacks were boosted to $2.1 billion, up $200 million from the initial plan, and the balance sheet remains robust. The strategic logic echoes a theme the company has repeated for a year — that the grocery business, not banking, is the growth engine — but the completion of the sale marks a real inflection point, not just another EQ Bank partnership update.

The GLP-1 Inflection Point

Perhaps the most consequential narrative shift in this call is the pharmacy story. With GLP-1 drugs going generic, Loblaw is no longer merely a dispenser of expensive branded therapies — it's preparing for a volume-driven windfall. The data presented was strikingly specific:

our data is telling us that next year, GLP-1 sales despite the price decrease, should grow double digit, okay, in dollars. And that you are going to see gross profit dollars and gross profit rate grow way more than that.
Richard Dufresne, Chief Financial Officer · 2026-07-30

This is the third consecutive call where GLP-1 has been a central topic, but the tone has shifted decisively from uncertainty to conviction. On the July 2025 call, management was more measured, noting "I think when prices come down, which we believe they will, I think we will have more customers that will be able to utilize this GLP-1 drug" (“...more customers that will be able to utilize this GLP-1 drug” — Unidentified Company Representative, Executive (likely President and CEO or other senior executive) · 2025-07-24) — a defensive posture. Now, they are modeling a double-digit dollar growth year with even stronger gross profit dollar expansion. The early read-through is encouraging: "within this category, we are beginning to see the impact of GLP 1 drugs going generic. it is still very early, but the initial indications are encouraging. Lower generic pricing is being offset by higher volumes." This is a classic generic-inflation inflection — more patients, lower prices, higher margins — and it's a company-specific catalyst that the broader market tracker is only beginning to price in, as evidenced by the appearance of "Wegovy Pill" and "Weight health" in the 20253-20254 global keyword trajectory.

Value-Minded Consumers, Double-Digit New Stores

The retail engine remains the core story. Consumers are relentlessly seeking value, and Loblaw's discount banners are the primary beneficiary. Per Bank described the consumer environment in stark terms: “Customers are looking for value. Using promotions, engaging with PC Optimum offers, and making choices across the basket to manage their budgets.” — Per Bank, President and Chief Executive Officer · 2026-07-30 Hard discount comparable sales were close to 4%, and management noted a meaningful behavioral shift — a 500-basis-point increase in frozen vegetable sales in those banners, as consumers trade down to manage inflation. The T&T expansion into the US remains a bright spot with an almost absurd level of outperformance — the San Jose store "generated the highest first week sales of any store opening in the history of Loblaw," a record that underscores the banner's resonance. This echoes the enthusiasm of the February 2025 call, where management said, "we're just overwhelmed with the success that Tina Lee and the team are having in the US" (“we're just overwhelmed with the success that Tina Lee and the team are having in the US” — Per Bank, President and Chief Executive Officer · 2025-02-20). Now with two more California stores planned for 2026, the US trial is becoming a meaningful growth vector. Underlying this is a consistent commitment to square footage growth — roughly 75 stores this year, with a similar pace next year — which management frames as structural tailwind once new stores mature. The consumer preference for discount is described as a long-term shift, not a cyclical blip, and the company is deliberately positioned to capture it. Intriguingly, while the global market is obsessed with IEEPA tariff refunds — a top global keyword in the most recent quarter — Loblaw treats tariffs as a transient, profit-neutral headwind: a 40-basis-point swing from last year's retail price increases on direct US imports that will "disappear again in October." This contrast highlights Loblaw's resilience: it's not banking on a windfall to hit its numbers; it's baking in a short disruption that reverses itself, while the real value creation is coming from generics and discount-led volume growth.